Head-to-head evidence
Glycopyrrolate/formoterol fumarate vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Umeclidinium/Vilanterol's landscape